Pre-AMNOG drugs wriggle off Germany's retrospective assessment hook, but no escape for Novartis
This article was originally published in Scrip
Executive Summary
All marketed products which had been netted by Germany's pricing and reimbursement agency to face a retrospective assessment could be off the hook under the new coalition government, which has proposed a change to the controversial AMNOG law abolishing benefit assessments for pre-AMNOG drugs. But the policy comes too late for the gliptin class, including Novartis' Galvus (vildagliptin), which has already been caught and weighed and now faces major price cuts.